The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -81.99%.However, over the last six months, we can see a stronger performance of -78.81%. Over the last 30 days, the price of CYCC has leaped by -39.51%. And in the last five days, it has fallen by -23.27%.
Cyclacel Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $9.69 on 11/09/23 and the lowest value was $0.38 on 11/07/24.
52-week price history of CYCC Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cyclacel Pharmaceuticals Inc’s current trading price is -95.04% away from its 52-week high, while its distance from the 52-week low is 28.27%. The stock’s price range during this period has varied between$0.38 and $9.69. The Cyclacel Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.67 million for the day, a figure considerably higher than their average daily volume of 1.09 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cyclacel Pharmaceuticals Inc (CYCC) has experienced a quarterly decline of -64.97% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.16M.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2166, with a change in price of -1.0190. Similarly, Cyclacel Pharmaceuticals Inc recorded 766,975 in trading volume during the last 100 days, posting a change of -67.93%.
CYCC’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CYCC stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
CYCC Stock Stochastic Average
Cyclacel Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 5.01%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 5.01%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 2.69% and 1.44%, respectively.
